UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-Q/A
(Amendment No. 1)
| x | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIESEXCHANGE ACT OF 1934 |
| For the quarterly period ended June 30, 2012 |
OR
| ¨ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIESEXCHANGE ACT OF 1934 |
| For the transition period from to |
Commission file number 001-35050
ENDOCYTE, INC.
(Exact name of Registrant as specified in its charter)
| Delaware | 35-1969-140 |
| (State or other jurisdiction of | (I.R.S. Employer |
| incorporation or organization) | Identification Number) |
3000 Kent Avenue, Suite A1-100
West Lafayette, IN 47906
(Address of Registrant’s principal executive offices)
Registrant’s telephone number, including area code: (765) 463-7175
Securities registered pursuant to Section 12(b) of the Act:
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yesx No¨
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yesx No¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):
| Large accelerated filer ¨ | Accelerated filer ¨ | Non-accelerated filerx | Smaller reporting company¨ |
| (Do not check if a smaller reporting company) | |||
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes¨Nox
Number of shares of the registrant’s Common Stock, $0.001 par value, outstanding on July 30, 2012: 35,870,868
EXPLANATORY NOTE
This Amendment on Form 10-Q/A is being filed for the sole purpose of refiling Exhibits 31.1 and 31.2 which inadvertantly omitted a portion of paragraph 4 of such certifications.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this amended report to be signed on its behalf by the undersigned, thereunto duly authorized.
| ENDOCYTE, INC. | ||
| Date: September 7, 2012 | By: | /s/ P. Ron Ellis |
| P. Ron Ellis | ||
| President and Chief Executive Officer | ||
| (Principal Executive Officer) | ||
| Date: September 7, 2012 | By: | /s/ Michael A. Sherman |
| Michael A. Sherman | ||
| Chief Financial Officer | ||
| (Principal Financial Officer) | ||
| Date: September 7, 2012 | By: | /s/ Beth A. Taylor |
| Beth A. Taylor | ||
| Corporate Controller | ||
| (Principal Accounting Officer) | ||
